Clinical Trial Update: Loncastuximab Tesirine in WM [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing Loncastuximab tesirine for Waldenström macroglobulinemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenstrom Macroglobulinemia

Drugs mentioned

• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: Shayna Sarosiek, MD | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: RECRUITING